Research Analysts’ Weekly Ratings Updates for Rallybio (RLYB)

Rallybio (NASDAQ: RLYB) recently received a number of ratings updates from brokerages and research firms:

• 10/12/2025 – Rallybio was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 10/8/2025 – Rallybio had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/4/2025 – Rallybio was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 9/27/2025 – Rallybio had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 8/23/2025 – Rallybio was upgraded by analysts at Wall Street Zen to a “sell” rating.

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.